Verrica (VRCA) Q1 2026 earnings review
Record Volume Outpaces Revenue as Pricing Pressures and Cash Burn Mount
Verrica delivered record demand for YCANTH in Q1 2026, dispensing over 15,300 units. However, a major disconnect has emerged: while unit volume surged 51% YoY, net product revenue only grew 25%. This severe contraction in revenue-per-unit highlights the margin drag of the company's aggressive copay assistance programs. Compounding the pricing pressure is a precarious balance sheet. With cash dropping to $20.6 million and net losses remaining near $10 million per quarter, Verrica faces a critical liquidity cliff within the next six to nine months unless non-dilutive partnerships or capital raises are executed.
🐂 Bull Case
YCANTH achieved record unit volume in March, overcoming January weather disruptions. Exceeding 100,000 lifetime units proves the drug is cementing its position as the standard of care for molluscum.
Torii Pharmaceutical's successful launch of YCANTH in Japan provides vital validation and new royalty streams, while the COVE-2 common warts trial is already 50% enrolled.
🐻 Bear Case
The gap between volume growth (+51%) and revenue growth (+25%) is alarming. Verrica is essentially buying market share through its $25 patient co-pay program, severely compressing revenue realization.
Cash reserves plunged by $9.5M in a single quarter to $20.6M. With SG&A costs accelerating due to sales force expansion, the company has less than three quarters of runway remaining.
⚖️ Verdict: 🔴
Bearish. While management celebrates unit volume and pipeline progress, the financial reality is stark. Falling revenue per unit combined with a dwindling cash runway overshadows the operational victories.
Key Themes
YCANTH Unit Volume Accelerating
Despite a January slowdown caused by winter weather on the East Coast (Macro headwind), Q1 2026 demand re-accelerated sharply in February and March. Total dispensed applicator units hit 15,302, marking a 12.1% sequential increase and pushing the company past the 100,000 cumulative unit milestone. The expansion of the sales force is demonstrably moving the needle on prescribing behavior.
The Gross-to-Net Decoupling
A critical red flag: YCANTH unit volume grew 51.3% YoY, but corresponding U.S. product revenue grew only 25.4% YoY. This implies the net revenue realized per dispensed unit has fallen drastically. Management is trading margin for volume via aggressive patient assistance programs (capping co-pays at $25), which raises questions about the ultimate profitability of the molluscum indication.
Looming Liquidity Crisis
Verrica is burning cash at a dangerous rate. The cash balance dropped from $30.1M at the end of 2025 to just $20.6M at the end of Q1 2026. With operating expenses accelerating (Total OPEX $14.7M) and net losses at $9.7M for the quarter, the company has roughly two quarters of operational runway left. Management must execute a partnership or a highly dilutive capital raise immediately.
Strategic Torii Partnership Subsidizes Growth
The Torii Pharmaceutical collaboration continues to be Verrica's financial lifeline. Torii officially launched YCANTH in Japan in Q1 2026 (generating $0.7M in commercial supply revenue for Verrica). More importantly, Torii is funding the first $40 million of the global Phase 3 common warts program, which is keeping Verrica's R&D expenses artificially low while advancing a major label expansion.
VP-315 Shows Abscopal Promise
Innovation remains a bright spot. Verrica announced that Phase 2 data for VP-315 (oncolytic peptide for basal cell carcinoma) demonstrates an abscopal-like effect in non-treated lesions. This biological activity validates the mechanism of action and makes the asset significantly more attractive for a potential multi-billion dollar out-licensing deal, which is desperately needed to replenish the balance sheet.
East Coast Winter Weather Hits January
Management explicitly cited winter weather across the East Coast as a macro headwind that negatively impacted dispensing in January. While demand recovered in February and March, it highlights the vulnerability of physician-administered topical treatments to seasonal patient traffic disruptions.
Other KPIs
Accelerating. Up from $8.8M in Q1 2025. The $1.3M increase (excluding stock-based comp) is directly tied to the expansion of the commercial sales force. While driving record units, this aggressive commercial spend is severely testing the company's limited cash reserves.
Reversing/Worsening. The weighted average common shares outstanding jumped 124% YoY from 9.48M in Q1 2025 to 21.3M in Q1 2026. This severe dilution masks the flat net loss (-$9.7M in both quarters), making the EPS appear to improve (-$0.45 vs -$1.03) purely due to a ballooning share count.
Stable/Improving. A massive drop from $2.2M in Q1 2025 following the settlement and termination of the debt facility in November 2025. This removes a significant debt service overhang, though the operational burn rate remains high.
Guidance
Management expects to initiate the second Phase 3 trial (COVE-3) in the U.S. and Japan in mid-2026. The first trial (COVE-2) is already over 50% enrolled. This timeline is stable and crucial for unlocking the 22-million patient common warts market.
Key Questions
Gross-to-Net Stabilization
With unit volume growing at double the rate of net revenue, what is the floor for your gross-to-net realization? At what point does the $25 co-pay program cease to be accretive to the bottom line?
Cash Runway and Funding Strategy
You exited Q1 with $20.6 million in cash and a ~$9.5 million quarterly burn. How do you plan to fund operations past Q3 2026 without accessing highly dilutive equity markets?
VP-315 Partnership Timing
Given the compelling abscopal data expected at SID 2026, what is the realistic timeline for securing a strategic partner for VP-315, and will that partnership involve upfront cash to bridge your current liquidity gap?